# Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug

> **NCT00988936** · PHASE2 · COMPLETED · sponsor: **Siemens Molecular Imaging** · enrollment: 35 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Metastatic Colon/Rectum Cancer
- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** [F-18]RGD-K5

## Key facts

- **NCT ID:** NCT00988936
- **Lead sponsor:** Siemens Molecular Imaging
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-03
- **Final completion:** 2012-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2012-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988936, "Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00988936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*